A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass

NCT04615910 · Unknown status

Last updated 2026-05-28

This clinical trial is testing a new imaging method using a special radioactive tracer to study the effects of a diabetes treatment on the insulin-producing cells in the pancreas of people with diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, single-blind basic-science study

Participants 30 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2021-07 · est. completion 2025-07

Where 2 sites · Austria, France

What this study is testing ClinicalTrials.gov NCT04615910 ↗

Description as written by the study sponsor.

The goal of the trial is to measure pancreatic uptake of 68Ga-NODAGA-exendin by PET/CT for detection of intra-individual differences in beta cell mass before and after treatment with Verapamil.

Treatments tested

68Ga-NODAGA-exendin-4 PET/CT Radiation

68Ga-NODAGA-exendin-4 PET/CT

Main thing measured	Pancreatic 68Ga-exendin uptake
Sponsor	Radboud University Medical Center
Conditions studied	Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04615910 ↗